Want to see GB:EDEN full AI Analyst Report?
Top Page
Eden Research
(LSE:EDEN)
Select Model
Select Model
Rating:50Neutral
Price Target:
3.00 p
â–²(36.36% Upside)
Action:Reiterated
Date:10/31/26
The score is held back primarily by weak financial performance: persistent losses and recurring cash burn despite a strong, low-debt balance sheet. Technicals are supportive of an uptrend, but extremely overbought readings elevate near-term reversal risk. Valuation is constrained by a negative P/E and no provided dividend yield, and there is no actionable earnings-call detail to shift the outlook.
Positive Factors
Bio-based crop protection technology
Eden’s terpene-based encapsulation platform supports multiple agricultural and crop-storage applications, giving the company a technology base that can be reused across products and markets. This breadth may support licensing, partner adoption and longer-term commercial expansion without relying on a single formulation.
Negative Factors
Persistent operating and net losses
Eden has not yet demonstrated sustainable profitability despite generating positive gross profit. Continuing operating and net losses reduce internally funded investment capacity, weaken returns on shareholder capital and increase the importance of successful commercial execution before the business can establish durable earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Bio-based crop protection technology
Eden’s terpene-based encapsulation platform supports multiple agricultural and crop-storage applications, giving the company a technology base that can be reused across products and markets. This breadth may support licensing, partner adoption and longer-term commercial expansion without relying on a single formulation.
Read all positive factors
Eden Research (EDEN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£25.31M
Dividend YieldN/A
Average Volume (3M)483.19K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees23
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding803,363,000
10 Day Avg. Volume619,028
30 Day Avg. Volume483,192
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.22
Price to Sales (P/S)3.90
P/FCF Ratio-6.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£6.10M
Eden Research Business Overview & Revenue Model
Company Description
Eden BioSolutions Plc offers sustainable solutions for crop protection, animal health and consumer products in the United Kingdom and rest of Europe. The firm provides various plant protection products, such as foliar disease control, soil pest, p...
How the Company Makes Money
Eden Research primarily makes money by commercialising its bio-based crop protection products and technology through licensing and distribution arrangements with partners. Revenue is generated mainly from (1) product sales and related partner purc...
Eden Research Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.62M | 3.88M | 4.30M | 3.19M | 1.83M | 1.23M |
| Gross Profit | 1.39M | 1.14M | 1.87M | 1.77M | 207.14K | 28.32K |
| EBITDA | -1.68M | -1.56M | -1.59M | -6.24M | -1.83M | -2.72M |
| Net Income | -2.35M | -1.96M | -1.91M | -6.49M | -2.24M | -2.79M |
Balance Sheet | ||||||
| Total Assets | 13.46M | 16.34M | 15.41M | 16.59M | 12.91M | 15.03M |
| Cash, Cash Equivalents and Short-Term Investments | 1.85M | 1.52M | 3.67M | 7.41M | 1.99M | 3.83M |
| Total Debt | 571.86K | 671.91K | 168.73K | 229.77K | 355.32K | 398.35K |
| Total Liabilities | 2.85M | 3.91M | 3.57M | 3.05M | 2.17M | 2.20M |
| Stockholders Equity | 10.58M | 12.42M | 11.82M | 13.52M | 10.72M | 12.80M |
Cash Flow | ||||||
| Free Cash Flow | -710.00K | -2.45M | -3.60M | -1.80M | -1.74M | -3.34M |
| Operating Cash Flow | -209.90K | -2.44M | -1.01M | -1.70M | -683.10K | -1.62M |
| Investing Cash Flow | -2.72M | -2.41M | -2.48M | -1.72M | -1.05M | -1.73M |
| Financing Cash Flow | -150.87K | 2.64M | -155.53K | 8.90M | -150.35K | -90.39K |
Eden Research Technical Analysis
Positive
2.20
Price Trends
2.32
Positive
2.55
Positive
3.03
Positive
Market Momentum
0.16
Negative
92.29
Negative
84.72
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EDEN, the sentiment is Positive. The current price of 2.2 is below the 20-day moving average (MA) of 2.53, below the 50-day MA of 2.32, and below the 200-day MA of 3.03, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 92.29 is Negative, neither overbought nor oversold. The STOCH value of 84.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EDEN.
Eden Research Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | £5.09B | 64.43 | 3.65% | 3.05% | 3.36% | -43.08% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | £1.06B | 19.35 | 11.29% | 1.78% | -11.73% | ― | |
58 Neutral | £23.94M | -25.55 | -15.42% | ― | 57.55% | 2.94% | |
53 Neutral | £181.98M | -1.52 | -13.27% | 9.77% | -4.98% | -43.98% | |
50 Neutral | £25.31M | -8.75 | -16.16% | ― | ― | ― |
* Basic Materials Sector Average
GB:EDEN
Eden Research
3.15
0.65
26.00%
GB:CRDA
Croda International
3,644.00
919.53
33.75%
GB:ELM
Elementis
187.20
25.84
16.01%
GB:ITX
Itaconix
177.50
74.00
71.50%
GB:SYNT
Synthomer
111.00
58.70
112.24%
Eden Research Corporate Events
Business Operations and Strategy
Eden BioSolutions targets partnerships at global biocontrol summit
Positive
Oct 19, 2026
Eden BioSolutions will send its chief executive Sean Smith, chief financial officer Alex Abrey and other commercial team members to the Annual Biocontrol Industry Meeting in Basel from 20 to 22 October 2026. The event is a key gathering for the gl...
Business Operations and StrategyShareholder Meetings
Eden BioSolutions plans investor update as sustainable biopesticide portfolio grows
Positive
Oct 6, 2026
Eden BioSolutions plc, a specialist in sustainable biopesticides and biocontrol technologies, serves global agriculture and related sectors with plant‑based crop protection products and plastic‑free microencapsulation solutions. Its co...
Business Operations and Strategy
Eden Research Rebrands as Eden BioSolutions to Sharpen Biopesticide Focus
Positive
Oct 1, 2026
Eden BioSolutions, a UK-listed leader in sustainable biopesticides and biocontrol technologies, serves global crop protection, animal health and consumer markets with plant-derived products aimed at high-value fruits, vegetables and seed treatment...
Business Operations and StrategyShareholder Meetings
Eden Research Wins AGM Backing and Rebrands as Eden BioSolutions
Positive
Sep 29, 2026
Eden Research plc, the AIM-quoted biopesticides specialist, has secured strong shareholder backing at its Annual General Meeting, with all resolutions passed, including the reappointment of board members and authorities related to share issuance a...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Eden Research uses AGM to showcase regulatory wins and expanding biopesticide pipeline
Positive
Sep 29, 2026
Eden Research’s AGM statement highlights continued momentum in building its position as an emerging leader in biological crop protection, with fresh commercial and regulatory milestones for its existing products. Recent progress includes Cal...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Eden Research Wins EPA Label Expansion for Mevalone in Key U.S. Market
Positive
Sep 28, 2026
Eden Research, the only UK-listed company focused solely on biopesticides for sustainable agriculture, develops terpene-based crop protection products and plastic-free Sustaine microencapsulation for use on high-value fruits, vegetables and other ...
Business Operations and StrategyExecutive/Board Changes
Eden Research Grants Long-Term Incentive Options Tied to Shareholder Returns and Revenue Targets
Positive
Sep 17, 2026
Eden Research has granted 33,737,659 options over new ordinary shares under its Long Term Incentive Plan for calendar year 2025, aligning staff rewards with future performance. The awards include 7,101,189 options for chief executive Sean Smith, 5...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Eden Research posts 2026 accounts and sets date for AGM
Positive
Sep 7, 2026
Eden Research plc, the AIM‑quoted biopesticides and biocontrol specialist, has published its Annual Report and Accounts for the fifteen‑month period to 31 March 2026 and circulated the Notice of its upcoming Annual General Meeting. The...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Eden Research boosts revenue and global approvals as losses widen
Positive
Aug 26, 2026
Eden Research reported preliminary results for the 15 months to 31 March 2026, with revenue rising to £4.9 million but operating losses widening to £2.9 million and cash falling to £1.5 million. The company completed a £10.8 mi...
Business Operations and StrategyFinancial Disclosures
Eden Research sets date for 2026 preliminary results and investor briefing
Positive
Aug 25, 2026
Eden Research plc, a UK-listed leader in sustainable biopesticides and biocontrol technologies, develops plant-derived crop protection products and a biodegradable microencapsulation platform for global agriculture and related markets. Its key off...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Eden Research Wins Mevalone Approvals in Slovakia and Egypt, Opening North African Market
Positive
Aug 4, 2026
Eden Research has secured regulatory approvals for its Botrytis fungicide Mevalone in Slovakia and, under the Trilogy brand, in Egypt, extending its reach in both Central Europe and North Africa. In Slovakia, the product will be marketed by Biocon...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.